< Back To List
Alvin Luk
- President & Chief Medical Officer (Group); Chief Executive Officer (U.S.A.) HanchorBio (漢康生技)
Reprogramming the CD47–SIRPα Axis in Cancer Immunotherapy: Clinical Validation and Next-Generation Multi-Checkpoint Engineering
| Role | Speaker |
| Date & Time | 05/02 10:00 - 11:00 |
| Room | 701D |
Beyond CD47 Blockade: Redefining the CD47-SIPRα Field for Next-Generation Innate Immunotherapy
| Role | Speaker |
| Date & Time | 05/02 15:05 - 15:55 |
| Room | 701D |
Education / Training
MBA, Harvard Business School
PhD., Neuroscience, University of California, San Francisco
M.S., Cell Development & Physiology, University of California, Berkeley
B.S., Biochemistry, University of California, Berkeley
Professional and Research Experience
Broad of Directors Member, HanchorBio (漢康生技)
Global Senior Clinical Advisor, HanchorBio/Hanchor Biopharma (漢康生物)
Chairman of Scientific Advisory Board, Zhongmou Therapeutics (中眸醫療科技)
Co-Founder, CEO, and Board of Directors Member, HuidaGene Therapeutics (輝大基因)
Awards & Honors
2025
TIME100 Health Honoree (2025)
2008
Bayer® Star Award
2004
American Society of Hematology Excellence Award